Friday, 1 March 2019

ImmunoGen's ovarian cancer drug fails in late-stage study

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)